Literature DB >> 9311827

Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

A Björndal1, H Deng, M Jansson, J R Fiore, C Colognesi, A Karlsson, J Albert, G Scarlatti, D R Littman, E M Fenyö.   

Abstract

The biological phenotype of primary human immunodeficiency virus type 1 (HIV-1) isolates varies according to the severity of the HIV infection. Here we show that the two previously described groups of rapid/high, syncytium-inducing (SI) and slow/low, non-syncytium-inducing (NSI) isolates are distinguished by their ability to utilize different chemokine receptors for entry into target cells. Recent studies have identified the C-X-C chemokine receptor CXCR4 (also named fusin or Lestr) and the C-C chemokine receptor CCR5 as the principal entry cofactors for T-cell-line-tropic and non-T-cell-line-tropic HIV-1, respectively. Using U87.CD4 glioma cell lines, stably expressing the chemokine receptor CCR1, CCR2b, CCR3, CCR5, or CXCR4, we have tested chemokine receptor specificity for a panel of genetically diverse envelope glycoprotein genes cloned from primary HIV-1 isolates and have found that receptor usage was closely associated with the biological phenotype of the virus isolate but not the genetic subtype. We have also analyzed a panel of 36 well-characterized primary HIV-1 isolates for syncytium induction and replication in the same series of cell lines. Infection by slow/low viruses was restricted to cells expressing CCR5, whereas rapid/high viruses could use a variety of chemokine receptors. In addition to the regular use of CXCR4, many rapid/high viruses used CCR5 and some also used CCR3 and CCR2b. Progressive HIV-1 infection is characterized by the emergence of viruses resistant to inhibition by beta-chemokines, which corresponded to changes in coreceptor usage. The broadening of the host range may even enable the use of uncharacterized coreceptors, in that two isolates from immunodeficient patients infected the parental U87.CD4 cell line lacking any engineered coreceptor. Two primary isolates with multiple coreceptor usage were shown to consist of mixed populations, one with a narrow host range using CCR5 only and the other with a broad host range using CCR3, CCR5, or CXCR4, similar to the original population. The results show that all 36 primary HIV-1 isolates induce syncytia, provided that target cells carry the particular coreceptor required by the virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311827      PMCID: PMC192094          DOI: 10.1128/JVI.71.10.7478-7487.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Isolation and characterization of human immunodeficiency virus type 1 variants infectious to brain-derived cells: detection of common point mutations in the V3 region of the env gene of the variants.

Authors:  N S Shimizu; N G Shimizu; Y Takeuchi; H Hoshino
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 2.  Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research.

Authors:  M P D'Souza; V A Harden
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

3.  Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes.

Authors:  J Louwagie; F E McCutchan; M Peeters; T P Brennan; E Sanders-Buell; G A Eddy; G van der Groen; K Fransen; G M Gershy-Damet; R Deleys
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

4.  The biological phenotype of HIV-1 is usually retained during and after sexual transmission.

Authors:  J R Fiore; A Björndal; K A Peipke; M Di Stefano; G Angarano; G Pastore; H Gaines; E M Fenyö; J Albert
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

5.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

7.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.

Authors:  A Von Gegerfelt; J Albert; L Morfeldt-Månson; K Broliden; E M Fenyö
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

9.  Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype.

Authors:  G Scarlatti; V Hodara; P Rossi; L Muggiasca; A Bucceri; J Albert; E M Fenyö
Journal:  Virology       Date:  1993-12       Impact factor: 3.616

10.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  A Karlsson; K Parsmyr; E Sandström; E M Fenyö; J Albert
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

View more
  260 in total

1.  Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; Y Yi; J C Grivel; A Singh; D Schols; E De Clercq; R G Collman; L Margolis
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus.

Authors:  R D Berkowitz; A B van't Wout; N A Kootstra; M E Moreno; V D Linquist-Stepps; C Bare; C A Stoddart; H Schuitemaker; J M McCune
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.

Authors:  H Petry; K Pekrun; G Hunsmann; E Jurkiewicz; W Lüke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV.

Authors:  A D Sullivan; J Wigginton; D Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

7.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

8.  Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.

Authors:  A Singh; R G Collman
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

10.  Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.

Authors:  M Cayabyab; S Hinuma; M Farzan; H Choe; S Fukusumi; C Kitada; N Nishizawa; M Hosoya; O Nishimura; T Messele; G Pollakis; J Goudsmit; M Fujino; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.